Literature DB >> 8719235

Third-generation model for corticosteroid pharmacodynamics: roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver.

Z X Xu1, Y N Sun, D C DuBois, R R Almon, W J Jusko.   

Abstract

A third-generation pharmacokinetic/pharmacodynamic model was proposed for receptor/gene-mediated corticosteroid effects. The roles of the messenger RNA (mRNA) for the glucocorticoid receptor (GR) in hepatic GR down-regulation and the mRNA for hepatic tyrosine aminotransferase (TAT) induction by methylprednisolone (MPL) were examined. Male adrenalectomized Wistar rats received 50 mg/kg MPL iv. Blood and liver samples were collected at various time points for a period of 18 hr. Plasma concentrations of MPL, free hepatic cytosolic GR densities, GR mRNA, TAT mRNA, and TAT activities in liver were determined. Plasma MPL profile was biexponential with a terminal t1/2 of 0.57 hr. Free hepatic GR density rapidly disappeared from cytoplasm after the MPL dose and then slowly returned to about 60% of starting level after 16 hr. Meanwhile, GR mRNA level fell to 45% of baseline within 2 hr postdosing, and remained at that level for at least 18 hr. The GR down-regulation of GR mRNA and protein turnover rate were modeled. The TAT mRNA began to increase at about 2 hr, reached a maximum at about 5 hr, and declined to baseline by 14 hr. TAT induction followed a similar pattern, except the induction was delayed about 0.5 hr. Pharmacodynamic parameters were obtained by fitting seven differential equations in a piecewise fashion. The cascade of corticosteroid steps were modeled by a series of inductions for steroid-receptor-DNA complex, two intermediate transit compartments, TAT mRNA, and TAT activity. Results indicate that GR mRNA and TAT mRNA are major controlling factors for the receptor/gene-mediated effects of corticosteroids.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8719235     DOI: 10.1007/BF02354270

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  31 in total

Review 1.  Current models of steroid hormone action: a critique.

Authors:  J Gorski; F Gannon
Journal:  Annu Rev Physiol       Date:  1976       Impact factor: 19.318

2.  Molar quantification of specific messenger ribonucleic acid expression in northern hybridization using cRNA standards.

Authors:  D C DuBois; R R Almon; W J Jusko
Journal:  Anal Biochem       Date:  1993-04       Impact factor: 3.365

Review 3.  Glucocorticoid receptors and actions.

Authors:  A Munck; D B Mendel; L I Smith; E Orti
Journal:  Am Rev Respir Dis       Date:  1990-02

4.  Second generation model for prednisolone pharmacodynamics in the rat.

Authors:  A I Nichols; F D Boudinot; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1989-04

5.  In vitro RNA synthesis with SP6 RNA polymerase.

Authors:  P A Krieg; D A Melton
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

6.  Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data.

Authors:  C C Peck; S L Beal; L B Sheiner; A I Nichols
Journal:  J Pharmacokinet Biopharm       Date:  1984-10

Review 7.  Chronobiology and asthma. III. Timing corticotherapy to biological rhythms to optimize treatment goals.

Authors:  A Reinberg; M H Smolensky; G E D'Alonzo; J P McGovern
Journal:  J Asthma       Date:  1988       Impact factor: 2.515

8.  Methylprednisolone disposition in rabbits. Analysis, prodrug conversion, reversible metabolism, and comparison with man.

Authors:  W F Ebling; S J Szefler; W J Jusko
Journal:  Drug Metab Dispos       Date:  1985 May-Jun       Impact factor: 3.922

9.  Pharmacoimmunodynamics of methylprednisolone: trafficking of helper T lymphocytes.

Authors:  L E Fisher; E A Ludwig; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1992-08

10.  Receptor-mediated prednisolone pharmacodynamics in rats: model verification using a dose-sparing regimen.

Authors:  A I Nichols; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1990-06
View more
  19 in total

Review 1.  Interchangeability and predictive performance of empirical tolerance models.

Authors:  M Gårdmark; L Brynne; M Hammarlund-Udenaes; M O Karlsson
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

2.  Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.

Authors:  H Derendorf; B Meibohm
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

3.  A dispersion model for cellular signal transduction cascades.

Authors:  Murali Ramanathan
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

4.  Corticosteroid-regulated genes in rat kidney: mining time series array data.

Authors:  Richard R Almon; William Lai; Debra C DuBois; William J Jusko
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-06-28       Impact factor: 4.310

5.  SPLINDID: a semi-parametric, model-based method for obtaining transcription rates and gene regulation parameters from genomic and proteomic expression profiles.

Authors:  Kavitha Bhasi; Alan Forrest; Murali Ramanathan
Journal:  Bioinformatics       Date:  2005-08-11       Impact factor: 6.937

Review 6.  Applications of quantitative pharmacodynamic effect markers in drug target identification and therapy development.

Authors:  Robert M Straubinger; Wojciech Krzyzanski; Crystal M Francoforte; Jun Qu
Journal:  Anticancer Res       Date:  2007 May-Jun       Impact factor: 2.480

7.  NETWORKS, BIOLOGY AND SYSTEMS ENGINEERING: A CASE STUDY IN INFLAMMATION.

Authors:  P T Foteinou; E Yang; I P Androulakis
Journal:  Comput Chem Eng       Date:  2009-12-10       Impact factor: 3.845

8.  Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.

Authors:  Justin J Wilkins; Radojka M Savic; Mats O Karlsson; Grant Langdon; Helen McIlleron; Goonaseelan Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

Review 9.  Expanding clinical applications of population pharmacodynamic modelling.

Authors:  C Minto; T Schnider
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

10.  Modeling autonomic regulation of cardiac function and heart rate variability in human endotoxemia.

Authors:  Jeremy D Scheff; Panteleimon D Mavroudis; Steven E Calvano; Stephen F Lowry; Ioannis P Androulakis
Journal:  Physiol Genomics       Date:  2011-06-14       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.